Suggested remit: To appraise the clinical and cost effectiveness of epcoritamab within its marketing authorisation for relapsed or refractory follicular lymphoma.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6338
Provisional Schedule
- Committee meeting:
- 09 September 2025
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Warwick Evidence, Warwick Medical School, University of Warwick
Stakeholders
- Companies sponsors
- AbbVie (epcoritamab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Blood Cancer UK
- Follicular Lymphoma Foundation
- Lymphoma Action
- Professional groups
- Association of Cancer Physicians
- British Society for Haematology
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Advanz Pharma (lenalidomide) – not participating
- Amarox (lenalidomide) – not participating
- Biocon Pharma (lenalidomide) – not participating
- Bristol Myers Squibb (lenalidomide, lisocabtagene maraleucel) – not participating
- Celltrion Healthcare (rituximab) – not participating
- Dr Reddy’s Laboratories (bendamustine) – not participating
- Grindeks Kalceks UK (lenalidomide) – not participating
- Mylan (lenalidomide) – not participating
- Pfizer (rituximab) – not participating
- Piramal Critical Care (lenalidomide) – not participating
- Roche (obinutuzumab, rituximab)
- Sandoz (lenalidomide, rituximab) – not participating
- Seacross Pharmaceuticals (bendamustine) – not participating
- Sun Pharma (lenalidomide) – not participating
- Teva UK (lenalidomide) – not participating
- Thornton & Ross (lenalidomide) – not participating
- Zentiva (bendamustine) – not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 February 2025 | Invitation to participate |
| 13 November 2024 - 11 December 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6338 |
| 13 November 2024 | In progress. Scoping commencing |
| 07 November 2024 | Please note that this appraisal has been scheduled back into the work programme to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early February 2025 when we will write to you about how you can get involved. |
| 11 June 2024 | Suspended. The company has requested a delay to the evidence submission for this appraisal, therefore we will be terminating this topic ID number in line with receipt of the MA and a new topic ID will be scheduled and communicated to stakeholders. |
| 29 February 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early August 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 20 July 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual